Salarius Pharmaceuticals
An oncology based biotechnology company.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | $6.0m | Private Placement VC |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (34 %) | 313 % | 51 % | (65 %) | - | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (2607 %) | (273 %) | (150 %) | (699 %) | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (2616 %) | (200 %) | (140 %) | (694 %) | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 1421 % | 116 % | 132 % | 465 % | - | - | - |
Source: Company filings or news article
Related Content
Salarius Pharmaceuticals is a biotechnology company focused on developing innovative cancer treatments, particularly targeting epigenetic causes of sarcoma. The company operates in the biopharmaceutical market, primarily serving patients with rare and aggressive cancers. Salarius employs a research-driven business model, leveraging scientific advancements to create novel therapies. Revenue is generated through the development and commercialization of its proprietary drugs, as well as potential partnerships and grants. The company has been recognized for its contributions to oncology and has received significant funding, including an $18.7 million award from the Cancer Prevention and Research Institute of Texas (CPRIT).
Keywords: biotechnology, cancer treatment, epigenetics, sarcoma, oncology, rare cancers, drug development, biopharmaceutical, research-driven, CPRIT.
Tech stack
Investments by Salarius Pharmaceuticals
Edit